AbbVie Q4 GAAP loss $0.02 (emraclidine impairment), adj. EPS $2.16; FY rev $56.3B, 2025 adj. EPS guide $12.12-12.32

AbbVie Inc.

2024-FY EPS reported $2.39 revenue$56,334,000,000

Q4 revenue $15.102B (+5.6% reported); full-year revenue $56.334B (+3.7% reported).
Q4 GAAP diluted loss per share $0.02 (includes $3.5B impairment for emraclidine); adjusted diluted EPS $2.16.
Global Skyrizi revenue $3.778B (+57.7%) in Q4; Rinvoq revenue $1.834B (+46.2%); Humira revenue -49.1% to $1.682B.
2025 adjusted EPS guidance $12.12-$12.32; raises 2027 Skyrizi+Rinvoq revenue outlook to >$31B.
Full-year immunology revenue $26.682B (+2.1%); neuroscience $8.999B (+16.6%); aesthetics $5.176B (-2.2%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.